placebo + sorafenib

This is a combination regimen used in clinical trials, consisting of a placebo (an inactive substance) administered alongside sorafenib. Sorafenib is an oral small molecule multikinase inhibitor that targets several intracellular and cell surface kinases involved in tumor cell proliferation and angiogenesis. It inhibits the RAF/MEK/ERK pathway by blocking Raf serine/threonine kinases (including Raf-1, wild-type B-Raf, mutant B-Raf), as well as receptor tyrosine kinases such as VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, KIT, FLT3, RET/PTC. The combination "placebo + sorafenib" typically refers to the control arm in randomized controlled trials where patients receive both a placebo for another agent under investigation and active treatment with sorafenib. Sorafenib is primarily indicated for unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and differentiated thyroid carcinoma refractory to radioactive iodine treatment[1][2][3][4].